Screener / SEC EDGAR /CIK 0001739104 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Pharmaceuticals

Elanco Animal Health Inc ELAN

Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. 10-K, Item 1

Employees
1,000
Headquarters
Indianapolis, IN
CEO
Jeffrey N. Simmons
Next results
around Feb 23, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2024

Revenue of $4.4B through the costs to a net profit of $338.0M · income statement of the 10-K

8% net margin
Revenue to Gross profit: $2.4BRevenue to Cost of revenue: $2.0BGross profit to Net profit: $338.0MGross profit to Costs, tax, other: $2.1B Revenue: $4.4B REVENUE $4.4B +0% Y/Y Gross profit: $2.4B · 55% margin GROSS PROFIT $2.4B 55% margin · −2% Y/Y Cost of revenue: $2.0B · 45% of revenue COST OF REVENUE $2.0B 45% of revenue Net profit: $338.0M · 8% margin NET PROFIT $338.0M 8% margin Costs, tax, other: $2.1B · 47% of revenue COSTS, TAX, OTHER $2.1B 47% of revenue
Gross profit $2.4B 55% margin · −2% Y/Y
Net profit $338.0M 8% margin
The full income statement, year by year

ELAN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 6.2%, above 31% of 154 peers (their median 10.5%) REVENUE GROWTH 6.2% · above 31% Gross margin: 56.2%, above 38% of 107 peers (their median 63.8%) GROSS MARGIN 56.2% · above 38% Net margin: -2.9%, above 26% of 153 peers (their median 6.8%) NET MARGIN -2.9% · above 26% FCF margin: 7.9%, above 42% of 144 peers (their median 10.1%) FCF MARGIN 7.9% · above 42%
ELAN Peer median Below the median

What changed

6 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 25, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +8.4% ($805.0M to $873.0M) vs revenue +6.2% ($4.4B to $4.7B), +2.2 pts apart
  • Cash from operations $560.0M vs net income −$232.0M (FY ending Dec 31, 2025)
  • Inventory +10.4% ($1.6B to $1.7B) vs revenue +6.2% ($4.4B to $4.7B), +4.1 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: Valuation of goodwill in divestiture. Same as last year: United States (US) sales rebates and discounts
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

6 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 6 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We depend on sophisticated information technology (IT) systems and infrastructure.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We may be required to write down goodwill or other identifiable intangible assets.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We also have a series of cross-currency interest rate swaps (net investment hedges) to help mitigate the impact of currency rate fluctuations on our operations in Switzerland with tenors in August and November of 2026 and February of 2027. As of December 31, 2025, these net investment hedges have generated net losses of approximately…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    As a global company, we are subject to various state, federal and international laws and regulations, including regulations relating to the development, quality assurance, manufacturing, importation, distribution, marketing and sale of our products. These laws and regulations, and the approach taken by relevant authorities to enforce…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$4.4B$4.4B$4.4B$4.7B
Net income−$78.0M−$1.2B$338.0M−$232.0M
Operating cash flow$452.0M$271.0M$541.0M$560.0M
Free cash flow$281.0M$131.0M$394.0M$284.0M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$4.7B ▲ 6.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Elanco Animal Health Inc, Indianapolis, IN · from the 10-K filed Feb 24, 2026

Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve.

Headquarters
Indianapolis, IN
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 6, 2026

Employees, at the top of the page: "As of December 31, 2025, we employed over 1,000 employees in our global R&D and Regulatory Affairs organizations" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ELAN/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.